John C. Lechleiter
John C. Lechleiter (born 1952) is an American businessman and chemist. He serves as the President, Chief Executive Officer and Chairman of the Board of Directors of Eli Lilly and Company.
John C. Lechleiter was born in Louisville, Kentucky, on August 17, 1952. He is the eldest of nine children of Jeanne and John H. Lechleiter.
Lechleiter first participated in laboratory research in a summer research program at the University of Minnesota in 1974. Lechleiter received a Bachelor of Science in Chemistry from Xavier University in 1975. He went on to receive a master's degree and a PhD in organic chemistry from Harvard University in 1980 after studying on a National Science Foundation Fellowship. His thesis advisor was Dr. Paul A. Wender.
John C. Lechleiter and his wife Sarah live in Indianapolis, Indiana, have three children, Andrew, Daniel and Elizabeth, and now several grandchildren.
Lechleiter joined Eli Lilly and company in 1979 as senior organic chemist. From 1984 to 1986, he served as director of pharmaceutical product development at the Lilly Research Centre Limited in Windlesham, England. In 1986, he returned to the US as manager of research and development projects for Europe. He became Director of development projects management in 1988, Executive Director of pharmaceutical product development in 1991, Vice President of pharmaceutical product development in 1993, and Vice President of regulatory affairs in 1994. Lechleiter became Vice President for development and regulatory affairs in 1996, and Senior Vice President of pharmaceutical products in 1998. In 2001, he was appointed Executive Vice President for pharmaceutical products and corporate development. In a 2003 e-mail, he discussed the use of the anti-schizophrenia or bipolar disorder drug Zyprexa for "disruptive kids",(an "off-label" use, for which drug manufacturers are not legally permitted to encourage) even if it was not approved by federal regulators because it could lead to diabetes.“The fact we are now talking to child psychs and peds and others about Strattera means that we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population." In 2004, he became Executive Vice President for pharmaceutical operations.
...
Wikipedia